Welcome to the November Edition of our Newsletter!
November 2022 Newsletter
Welcome to the November edition of our newsletter!
Bringing you our latest discoveries in high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. Visit us at: moleculardevices.com
We are Molecular Devices: Helping scientists harness the full potential of biology
From our scientists and engineers to our service and support teams, we're passionate about equipping researchers with next-generation technology that advances scientific discovery. Our customers are at the heart of all we do, inspiring innovative solutions that unravel the complexity of biological systems and support the development of new therapeutics, to improve the quality of human life worldwide. We are Molecular Devices. Helping scientists harness the full potential of biology.
Molecular Devices expands global R&D hub in Austria
A ribbon-cutting ceremony celebrates the completed expansion of its Austrian Research & Development Center. Larger site will be future home of the Organoid Innovation Center – Salzburg, a collaborative space for advancing automated cell line development, organoid development, and screening solutions to improve drug discovery.
Biotechnology research tools to streamline production of food and beverage products
Similar to biologics, food products must undergo extensive regulatory oversight to ensure consumer safety and sustainable manufacturing practices. Our systems and support team have helped food and beverage groups across diverse business sectors by automating the manual processes that can slow down manufacturing and help ensure the quality, authenticity and safety.
Lab Automation Solutions: How to move from time-consuming processes to efficient workflows
Did you miss our live webinar on how automation can help researchers working with plate-based assays can move from time-consuming processes to efficient workflows? Don't worry, you can still watch it on-demand!
Automation and high-content imaging of 3D triple-negative breast cancer tumoroids
Triple negative breast cancer is a clinically aggressive tumor subtype with high rates of metastasis, recurrence, and drug resistance. Currently, there are no clinically approved small molecule targeted therapies for this disease, which underlines the critical need to discover new therapeutic targets.
In this application note, we describe automated imaging and cell culture methods to scale up complex 3D cell-based assays. Additionally, we share advanced analysis approaches that allow scientists to gain more information about complex cellular systems, disease phenotypes, and compound effects.
